Literature DB >> 4981497

Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results.

F Grumbach, G Canetti, M Le Lirzin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4981497

Source DB:  PubMed          Journal:  Tubercle        ISSN: 0041-3879


× No keyword cloud information.
  14 in total

1.  Intermittent treatment regimens in pulmonary tuberculosis.

Authors:  M Zierski
Journal:  Lung       Date:  1979       Impact factor: 2.584

Review 2.  New trends in the chemotherapy of tuberculosis--current aspects.

Authors:  M Zierski
Journal:  Pneumonologie       Date:  1974-06-14

Review 3.  General considerations in intermittent drug therapy of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Postgrad Med J       Date:  1971-11       Impact factor: 2.401

Review 4.  [Results of chemotherapy in tuberculosis].

Authors:  E Jancik
Journal:  Pneumonologie       Date:  1971

5.  Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong.

Authors:  M Aquinas; W G Allan; P A Horsfall; P K Jenkins; W Hung-Yan; D Girling; R Tall; W Fox
Journal:  Br Med J       Date:  1972-03-25

6.  Potentially serious side-effects of high-dose twice-weekly rifampicin.

Authors:  G Poole; P Stradling; S Worlledge
Journal:  Postgrad Med J       Date:  1971-11       Impact factor: 2.401

7.  Potentially serious side effects of high-dose twice-weekly rifampicin.

Authors:  G Poole; P Stradling; S Worlledge
Journal:  Br Med J       Date:  1971-08-07

8.  Intermittent chemotherapy in pulmonary tuberculosis--current aspects.

Authors:  M Zierski
Journal:  Pneumonologie       Date:  1972

9.  The scope of the controlled clinical trial, illustrated by studies of pulmonary tuberculosis.

Authors:  W Fox
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

Review 10.  Rifampicin: a review.

Authors: 
Journal:  Drugs       Date:  1971       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.